These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 23882255)
1. Formation and propagation of tau oligomeric seeds. Gerson JE; Kayed R Front Neurol; 2013; 4():93. PubMed ID: 23882255 [TBL] [Abstract][Full Text] [Related]
2. What is the evidence that tau pathology spreads through prion-like propagation? Mudher A; Colin M; Dujardin S; Medina M; Dewachter I; Alavi Naini SM; Mandelkow EM; Mandelkow E; Buée L; Goedert M; Brion JP Acta Neuropathol Commun; 2017 Dec; 5(1):99. PubMed ID: 29258615 [TBL] [Abstract][Full Text] [Related]
3. Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Stancu IC; Vasconcelos B; Ris L; Wang P; Villers A; Peeraer E; Buist A; Terwel D; Baatsen P; Oyelami T; Pierrot N; Casteels C; Bormans G; Kienlen-Campard P; Octave JN; Moechars D; Dewachter I Acta Neuropathol; 2015 Jun; 129(6):875-94. PubMed ID: 25862635 [TBL] [Abstract][Full Text] [Related]
4. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946 [TBL] [Abstract][Full Text] [Related]
5. Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. Shafiei SS; Guerrero-Muñoz MJ; Castillo-Carranza DL Front Aging Neurosci; 2017; 9():83. PubMed ID: 28420982 [TBL] [Abstract][Full Text] [Related]
6. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies. Navarrete LP; Pérez P; Morales I; Maccioni RB Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038 [TBL] [Abstract][Full Text] [Related]
7. Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody. Albert M; Mairet-Coello G; Danis C; Lieger S; Caillierez R; Carrier S; Skrobala E; Landrieu I; Michel A; Schmitt M; Citron M; Downey P; Courade JP; Buée L; Colin M Brain; 2019 Jun; 142(6):1736-1750. PubMed ID: 31038156 [TBL] [Abstract][Full Text] [Related]
8. The prion-like transmission of tau oligomers Jackson NA; Guerrero-Muñoz MJ; Castillo-Carranza DL Front Aging Neurosci; 2022; 14():974414. PubMed ID: 36062141 [TBL] [Abstract][Full Text] [Related]
9. Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease. Abskharon R; Seidler PM; Sawaya MR; Cascio D; Yang TP; Philipp S; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Felgner PL; Nakajima R; Glabe CG; Eisenberg DS J Biol Chem; 2020 Jul; 295(31):10662-10676. PubMed ID: 32493775 [TBL] [Abstract][Full Text] [Related]
10. The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome. Granholm AC; Hamlett ED J Clin Med; 2024 Feb; 13(5):. PubMed ID: 38592182 [No Abstract] [Full Text] [Related]
11. Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. DeVos SL; Corjuc BT; Oakley DH; Nobuhara CK; Bannon RN; Chase A; Commins C; Gonzalez JA; Dooley PM; Frosch MP; Hyman BT Front Neurosci; 2018; 12():267. PubMed ID: 29740275 [TBL] [Abstract][Full Text] [Related]
12. Azure C Targets and Modulates Toxic Tau Oligomers. Lo Cascio F; Kayed R ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132 [TBL] [Abstract][Full Text] [Related]
13. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Lasagna-Reeves CA; Castillo-Carranza DL; Jackson GR; Kayed R Curr Alzheimer Res; 2011 Sep; 8(6):659-65. PubMed ID: 21605039 [TBL] [Abstract][Full Text] [Related]
14. The role of tau oligomers in the onset of Alzheimer's disease neuropathology. Cárdenas-Aguayo Mdel C; Gómez-Virgilio L; DeRosa S; Meraz-Ríos MA ACS Chem Neurosci; 2014 Dec; 5(12):1178-91. PubMed ID: 25268947 [TBL] [Abstract][Full Text] [Related]
15. Dephosphorylation Passivates the Seeding Activity of Oligomeric Tau Derived From Alzheimer's Brain. Wu R; Li L; Shi R; Zhou Y; Jin N; Gu J; Tung YC; Liu F; Chu D Front Mol Neurosci; 2021; 14():631833. PubMed ID: 34054426 [TBL] [Abstract][Full Text] [Related]
16. Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. Vasconcelos B; Stancu IC; Buist A; Bird M; Wang P; Vanoosthuyse A; Van Kolen K; Verheyen A; Kienlen-Campard P; Octave JN; Baatsen P; Moechars D; Dewachter I Acta Neuropathol; 2016 Apr; 131(4):549-69. PubMed ID: 26739002 [TBL] [Abstract][Full Text] [Related]
17. Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. Vasili E; Dominguez-Meijide A; Outeiro TF Front Mol Neurosci; 2019; 12():107. PubMed ID: 31105524 [TBL] [Abstract][Full Text] [Related]
18. Tau Oligomers Neurotoxicity. Niewiadomska G; Niewiadomski W; Steczkowska M; Gasiorowska A Life (Basel); 2021 Jan; 11(1):. PubMed ID: 33418848 [TBL] [Abstract][Full Text] [Related]
19. The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease. Hopp SC; Lin Y; Oakley D; Roe AD; DeVos SL; Hanlon D; Hyman BT J Neuroinflammation; 2018 Sep; 15(1):269. PubMed ID: 30227881 [TBL] [Abstract][Full Text] [Related]
20. Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Lewis J; Dickson DW Acta Neuropathol; 2016 Jan; 131(1):27-48. PubMed ID: 26576562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]